Back to News
Market Impact: 0.1
SIBIONICS et PharmaSens explorent de nouvelles perspectives pour l'administration automatisée d'insuline lors du congrès de l'EASD 2026
Source: PR Newswire
Healthcare & BiotechTechnology & Innovation
Au congrès 2026 de l’EASD à Milan, SiBionics a présenté « See More, Act Earlier », une initiative reliant la surveillance continue à l’avenir de la prise en charge du diabète. L’extrait ne fournit ni résultats cliniques, ni données financières, ni détails supplémentaires sur l’initiative.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Samsung, SK Hynix shares drop as Q3 earnings loom
- DeepSeek set to raise at least $12 bln in Tencent, CATL-led round- Bloomberg
- Security researcher claims to they found KVM guest-host escape flaw
- Brazil Election: Bolsonaro Pushes Lula to Brink as Markets Set to Rally
- SpaceX stock climbs to highest since June, returning Musk to trillionaire status
- Security researcher claims they found KVM guest-host escape flaw
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Run Cost-Controlled Financial Research in AllMind Agent Studio
- State of Public Markets, June 2026: Higher for Longer Meets the AI Supercycle